Boryung Pharmaceutical Co., Ltd. Patent applications |
Patent application number | Title | Published |
20160022679 | PHARMACEUTICAL COMBINATION DRUG - The present invention relates to a pharmaceutical combination preparation comprising fimasartan and rosuvastatin as active ingredients together with meglumine. | 01-28-2016 |
20140256711 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same - Disclosed are an anti-angiogenic compound, represented by Chemical Formula I, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutically acceptable composition including the same. Because the compound of Chemical Formula I potently suppresses the angiogenesis, the compound of Chemical Formula I is applicable to the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor, and available as an anti-angiogenic agent. | 09-11-2014 |
20140044784 | COMBINED FORMULATION WITH IMPROVED STABILITY - Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability. | 02-13-2014 |
20100189717 | Plant Recombinant Human CTLA4IG and a Method for Producing the Same - The present invention provides a recombinant vector pBI-3D-hGalT or pBI-35S-hGalT containing a human β1,4-galactosyltransferase gene; a cell line transformed with a recombinant vector pMYN414 containing a cytotoxic T-lymphocyte anti-gen A-immunoglobulin (CTLA4Ig) fusion protein gene and the recombinant vector pBI-3D-hGalT or pBI-355-hGalT; and a method for producing a plant-derived recombinant human CTLA4Ig (CTLA4Igp) fusion protein with a human glycan structure using the same. The plant cell-derived recombinant human CTLA4Ig fusion protein (CTLA4Igp), which has a human glycan structure and is produced according to the present invention, exhibits an improved in vivo half life as compared to conventional plant-derived proteins, due to the presence of a human-like glycan structure. Consequently, the present invention using the plant expression system enables low-cost mass production of a CTLA4Igp fusion protein having an immunosuppressive activity comparable to that of the CTLA4IgM fusion protein expressed in conventional animal cell expression systems. | 07-29-2010 |
20090181428 | METHOD FOR PRODUCING TARGET PROTEINS USING AMINO ACIDS AND PYRUVIC ACIDS IN CULTURE OF PLANT CELLS - Provided is a method for producing a target protein via cultivation of transgenic plant cells comprising a promoter capable of expressing the protein under sugar-free conditions or in response to the depletion of sugar and a gene encoding the target protein, without exchange of a cell growth medium with a sugar-depleted medium. The method comprises 1) culturing transgenic plant cells in a sugar-rich medium to grow plant cells; and 2) culturing the transgenic plant cells with addition of an amino acid mixture to the culture of Step 1 without exchange of a cell growth medium with a sugar-depleted medium, thereby expressing a target protein. The method of the present invention enables commercial-scale production of recombinant proteins via establishment of optimized culture conditions by addition of an amino acid mixture to induce protein expression without exchange of a cell growth medium with a sugar-free medium, and addition of pyruvic acid during the induction period of protein expression to thereby enhance the production yield of target proteins. | 07-16-2009 |